The company does not operate its own manufacturing facilities for the clinical or commercial production of JAKAFI, ICLUSIG, PEMAZYRE, and OPZELURA, instead relying on third-party manufacturers for raw materials, active pharmaceutical ingredients (API), and finished drug products. For large molecule products MONJUVI/MINJUVI, ZYNYZ, and NIKTIMVO, the company utilizes a combination of third-party contracts and internal manufacturing, including a facility in Yverdon, Switzerland, which began producing MONJUVI/MINJUVI drug substance in late 2022. The supply chain involves multiple third parties responsible for raw materials, API production, finished dosage forms, and packaging. Specifically, ruxolitinib phosphate (the API for JAKAFI and OPZELURA) is produced by three qualified third-party contract manufacturers. JAKAFI and ICLUSIG have two qualified third-party manufacturers for commercial drug products, with secondary packaging of ICLUSIG performed by a third party. PEMAZYRE has one qualified third-party manufacturer for commercial drug products. OPZELURA has two qualified third-party manufacturers for the U.S. market and one additional qualified third-party manufacturer for commercial drug product sourcing.
Incyte's Comment on Supply Chain
The company does not operate its own manufacturing facilities for the clinical or commercial production of JAKAFI, ICLUSIG, PEMAZYRE, and OPZELURA, instead relying on third-party manufacturers for raw materials, active pharmaceutical ingredients (API), and finished drug products. For large molecule products MONJUVI/MINJUVI, ZYNYZ, and NIKTIMVO, the company utilizes a combination of third-party contracts and internal manufacturing, including a facility in Yverdon, Switzerland, which began producing MONJUVI/MINJUVI drug substance in late 2022. The supply chain involves multiple third parties responsible for raw materials, API production, finished dosage forms, and packaging. Specifically, ruxolitinib phosphate (the API for JAKAFI and OPZELURA) is produced by three qualified third-party contract manufacturers. JAKAFI and ICLUSIG have two qualified third-party manufacturers for commercial drug products, with secondary packaging of ICLUSIG performed by a third party. PEMAZYRE has one qualified third-party manufacturer for commercial drug products. OPZELURA has two qualified third-party manufacturers for the U.S. market and one additional qualified third-party manufacturer for commercial drug product sourcing.
Sources:
Incyte Corporation's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Incyte Corporation’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
